IκB-δ Inibidores

Os inibidores comuns do IκB-δ incluem, entre outros, o MG-132 [Z-Leu-Leu-Leu-CHO] CAS 133407-82-6, o inibidor IV do IKK-2 CAS 507475-17-4, o QNZ CAS 545380-34-5, o IMD 0354 CAS 978-62-1 e o Andrographolide CAS 5508-58-7.

IκB-δ inhibitors, as described above, work mainly by targeting the NF-κB signaling pathway, a key regulator in inflammatory responses, immune system activity and cell proliferation. The NF-κB pathway involves the phosphorylation and subsequent degradation of IκB proteins, leading to NF-κB translocating to the nucleus and activating target genes. As direct inhibitors of IκB-δ are scarce, these chemicals focus on upstream or parallel components of the NF-κB pathway, thus indirectly influencing IκB-δ activity. Compounds such as BAY 11-7082 and MG-132 target the stability and phosphorylation of IκB proteins, including IκB-δ. By inhibiting the phosphorylation of IκB-α or the activity of the proteasome, they prevent the degradation of IκB proteins, thus maintaining their inhibitory effect on NF-κB. Other inhibitors, such as IKK-2 Inhibitor IV and IMD-0354, specifically target the IκB kinase (IKK) complex, which is crucial for the phosphorylation of IκB proteins. Inhibition of IKKβ, a component of the IKK complex, leads to decreased phosphorylation of IκB and reduced NF-κB activity.

In addition, compounds such as QNZ and Andrographolide inhibit the NF-κB pathway by preventing the nuclear translocation of NF-κB subunits or by modifying key components of the pathway. Sulforaphane and wedelolactone act by modifying the cysteine residues in the IKK complex, affecting its kinase activity. These inhibitors demonstrate the various strategies employed to modulate the NF-κB/IκB-δ axis, from direct inhibition of the kinase to alterations in protein stability and nuclear translocation processes.